Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie av CDPATH™ för att hjälpa till att hantera och behandla Crohns sjukdom (COMPASS-CD)

5 oktober 2026 uppdaterad av: Takeda

En fas 4-studie som utvärderar verklig användning av CDPATH™, ett verktyg för att förutsäga risker för Crohns sjukdom

CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the potential path of their Crohn's disease. The number of visits will be decided by the study clinic according to their standard practice.

Studieöversikt

Status

Avslutad

Betingelser

Detaljerad beskrivning

The tool being tested in this study is called CDPATH™. CDPATH™ is being used to provide a graphical representation of an individual participant's risk of developing a CD-related complication within three years, leveraging known participant risk factors based on clinical, serologic and genetic variables to help people categorize risk who have CD. This study will gather data on the use of the tool in real-world settings to inform practical use of CDPATH™.

The study will enroll approximately 200 patients. Participants and health care providers (HCPs) will be surveyed to understand their satisfaction with the CDPATH™ process and with their treatment choice.

This multi-center trial will be conducted in the United States. The overall time to participate in this study is 36 months. Participants will make multiple visits to the HCP's clinic, and data will be collected approximately every six months up to 3 years, based on the timing of routine follow-up appointments for assessment.

Studietyp

Interventionell

Inskrivning (Faktisk)

241

Fas

  • Fas 4

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Arizona
      • Phoenix, Arizona, Förenta staterna, 85032
        • Arizona Arthritis & Rheumatology Research, PLLC
    • California
      • Loma Linda, California, Förenta staterna, 92357
        • VA Loma Linda Healthcare System
      • Murrieta, California, Förenta staterna, 92563
        • United Medical Doctors
      • Newport Beach, California, Förenta staterna, 92663
        • University of Southern California Medical Center
      • Orange, California, Förenta staterna, 92868
        • University of California at Irvine Medical Center
      • Orange, California, Förenta staterna, 92868
        • Clinnova Research Solutions
    • Colorado
      • Aurora, Colorado, Förenta staterna, 80014
        • Kaiser Permanate of Colorado
    • Connecticut
      • Hamden, Connecticut, Förenta staterna, 06518
        • Medical Research Center of Connecticut, LLC
    • Florida
      • Clearwater, Florida, Förenta staterna, 33762
        • West Central Gastroenterology d/b/a Gastro Florida
      • Pensacola, Florida, Förenta staterna, 32503
        • Gastroenterology Associates of Pensacola, PA
    • Idaho
      • Idaho Falls, Idaho, Förenta staterna, 83404
        • Grand Teton Research Group, PLL
    • Illinois
      • Arlington Heights, Illinois, Förenta staterna, 60005
        • GI Alliance
      • Gurnee, Illinois, Förenta staterna, 60031
        • GI Alliance
      • Northbrook, Illinois, Förenta staterna, 60062
        • Comprehensive Gastrointestinal Health
      • Rockford, Illinois, Förenta staterna, 61107
        • Rockford Gastroenterology Associates, Ltd.
    • Indiana
      • Indianapolis, Indiana, Förenta staterna, 46202
        • Indiana University
    • Iowa
      • Clive, Iowa, Förenta staterna, 50325
        • Iowa Digestive Disease Center
      • Iowa City, Iowa, Förenta staterna, 52242-1009
        • University of Iowa Hospitals & Clinics
    • Kansas
      • Kansas City, Kansas, Förenta staterna, 66160
        • University of Kansas Medical Center Research Institute, Inc.
    • Louisiana
      • Baton Rouge, Louisiana, Förenta staterna, 70809
        • GI Alliance - Baton Rouge
      • Shreveport, Louisiana, Förenta staterna, 71105
        • Louisiana Research Center, LLC
    • Maryland
      • Columbia, Maryland, Förenta staterna, 21045
        • Gastro Center of Maryland
    • Massachusetts
      • Burlington, Massachusetts, Förenta staterna, 01805
        • Lahey Clinic Inc. - PARENT ACCOUNT
      • Worcester, Massachusetts, Förenta staterna, 01655
        • UMASS Memorial Medical Center
    • New Mexico
      • Albuquerque, New Mexico, Förenta staterna, 87131-0001
        • University of New Mexico
    • New York
      • New York, New York, Förenta staterna, 10075-1850
        • Lenox Hill Hospital
    • Ohio
      • Beavercreek, Ohio, Förenta staterna, 45431
        • Clinical Inquest Center Ltd
      • Dayton, Ohio, Förenta staterna, 45415
        • Dayton Gastroenterology, Inc
    • Oregon
      • Portland, Oregon, Förenta staterna, 97220-9442
        • The Oregon Clinic, P.C.
    • Pennsylvania
      • Camp Hill, Pennsylvania, Förenta staterna, 17011
        • Susquehanna Research Group, LLC
      • Pittsburgh, Pennsylvania, Förenta staterna, 15213
        • University of Pittsburgh Medical Center Health System
      • Pittsburgh, Pennsylvania, Förenta staterna, 15212
        • Allegheny Center for Digestive Health
      • Uniontown, Pennsylvania, Förenta staterna, 15401
        • Frontier Clinical Research, LLC
    • South Carolina
      • Summerville, South Carolina, Förenta staterna, 29486
        • Palmetto Primary Care Physician Division of Gastroenterology
    • South Dakota
      • Rapid City, South Dakota, Förenta staterna, 57701
        • Rapid City Medical Center, LLC
    • Tennessee
      • Nashville, Tennessee, Förenta staterna, 37204
        • Vanderbilt University Medical Center
    • Texas
      • Austin, Texas, Förenta staterna, 78712
        • The University of Texas at Austin
      • Houston, Texas, Förenta staterna, 77030
        • Baylor College of Medicine
      • Southlake, Texas, Förenta staterna, 76092
        • GI Alliance - Southlake
    • Utah
      • Ogden, Utah, Förenta staterna, 84403
        • Care Access Research Berkley
      • Salt Lake City, Utah, Förenta staterna, 84132
        • University of Utah
    • Virginia
      • Fairfax, Virginia, Förenta staterna, 22031
        • GCGA Physicians LLC
      • Lynchburg, Virginia, Förenta staterna, 24502
        • Gastroenterology Associates
    • Washington
      • Bellevue, Washington, Förenta staterna, 98405
        • GI Alliance

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Has an initial diagnosis of CD established within five years prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report (if available).
  2. Has agreed to use the CDPATH™ tool.
  3. Has reliable access to the internet and is willing to answer electronic patient-reported outcomes (ePROs) throughout the study.

Exclusion Criteria:

  1. Has had known complications from CD including but not limited to: bowel stricture, CD-related intra-abdominal abscess, internal penetrating disease (known fistula other than perianal fistula), non-perianal surgery, bowel resection, or stricturoplasty. A perianal fistula or abscess without other signs of penetrating disease is allowed.
  2. Has had any non-CD-related abdominal surgery.
  3. Has received investigational biologic or nonbiologic agents for the treatment of CD in an investigational protocol. Approved biologic or nonbiologic agents for CD are allowed.
  4. Has previously used CDPATH™ or PROSPECT results to assess CD risk for complications.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Diagnostisk
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: CDPATH™

Participants with CD will be using CDPATH™ tool. Clinical data will be collected via an ongoing registry. Participants and health care provider (HCP)-reported outcomes data will be collected periodically once every 6 months for up to 36 months via electronic surveys. Two baseline blood samples will be collected at screening for CDPATH™ analysis. 1 additional sample will be collected for future potential biomarker analysis.

Crohn's disease risk prediction tool.

Andra namn:
  • UTSIKT

Three blood samples will be drawn.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Percentage of Participants in Real-world Practice in Each Risk Category at Baseline Based on the CDPATH™ Tool Results
Tidsram: Baseline (Day 1)

The risk profile of an individual participant with CD is the output of the CDPATH™ tool. Categories for CD includes low, medium, high risk of developing a CD complication within 3 years.

Baseline (Day 1)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Percentage of Participants with Specific Treatment Path and Choice Based on CDPATH™ Tool, Stratified According to Risk Category
Tidsram: Up to 36 months

Treatment path (i.e., sequence over time) and choice, by low, medium and high risk, will be chosen to characterize treatment path and choice based on risk stratification.

Up to 36 months
Change From Baseline in Decisional Conflict Scale (DCS) Score
Tidsram: Baseline, then every 6 months up to 36 months

DCS is a validated electronic patient-reported outcome (ePRO) collected via electronically administered patient surveys. It measures personal perceptions of the following responses: uncertainty in choosing options, modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in decision making, and effective decision making such as feeling the choice is informed, values-based, likely to be implemented and expressing satisfaction with the choice. DCS involves answering 11 questions of PRO, of which 10 questions can be answered as yes (score = 0) or unsure (score = 2) or no (score =4). The total score will range from 0 to 40. Higher score indicates higher decisional conflict.

Baseline, then every 6 months up to 36 months
Change From Baseline in Work Productivity and Activity Impairment Questionnaire - CD Version (WPAI-CD) Score
Tidsram: Baseline, then every 6 months up to 36 months

WPAI-CD is a validated ePRO collected via electronically administered patient surveys. It consists of six questions that evaluate 4 domain scores: absenteeism (i.e., work time missed), presenteeism (i.e., reduced work productivity), overall work impairment, and activity impairment. Scores are expressed as a percentage of impairment, where higher scores indicate greater impairment and reduced productivity. The total score ranges from 0 (no impairment) to 100% (total loss of work productivity).

Baseline, then every 6 months up to 36 months
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Scale Score
Tidsram: Baseline, then every 6 months up to 36 months

PROMIS Global Health scale is a validated ePRO collected via electronically administered patient surveys. It is a 10-item PRO measuring the overall evaluation of one's physical and mental health. The total score ranges from 0 to 100. The final score will be represented by the T-score metric, in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. A higher PROMIS T-score represents more of the concept being measured (higher Global Health score indicate better health).

Baseline, then every 6 months up to 36 months
Patient-Reported Satisfaction and Experience Score with the CDPATH™ Tool
Tidsram: Up to 36 months

Participant's satisfaction and experience with the CDPATH™ tool will be assessed based on 15 questions. Negative responses/lower score to/in these questions indicates less satisfaction whereas positive responses/higher score indicates satisfaction with the tool.

Up to 36 months
Number of Participants with Clinical Outcomes
Tidsram: Up to 36 months

Participants with clinical outcomes describing the disease burden based on treatment path and controlling for risk strata will be reported.

Up to 36 months
Percentage of Participants with Healthcare Resource Utilization
Tidsram: Up to 36 months

Healthcare resource includes healthcare provider (HCP) visits/referrals, visit to emergency room, hospitalizations, surgery, new CD-related complications, and diagnostic evaluations (e.g., imaging, colonoscopy, etc.).

Up to 36 months
Change from First Assessment in Health Care Provider (HCP)-reported Assessment of the Feasibility and Usability of the CDPATH™ Tool
Tidsram: First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)

HCP-reported CDPATH™ satisfaction data will be collected directly from HCPs via electronically administered HCP surveys and entered into the eCRF. HCPs will be queried regarding their satisfaction and experience with the general process, the ease of incorporating the tool in their everyday practice, and the impact of the tool on their treatment recommendations and participant communications. For the 6 questions, HCP will rate on 1-5 scale where, 1=strongly disagree and 5=strongly agree. For remaining 4 questions, written feedback from HCP will be consider. Overall positive responses will indicate higher feasibility and usability.

First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Studierektor: Study Director, Takeda

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

25 juni 2021

Primärt slutförande (Faktisk)

27 augusti 2026

Avslutad studie (Faktisk)

27 augusti 2026

Studieregistreringsdatum

Först inskickad

19 mars 2021

Först inskickad som uppfyllde QC-kriterierna

19 mars 2021

Första postat (Faktisk)

22 mars 2021

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

8 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

5 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Kriterier för IPD Sharing Access

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV
  • ICF
  • CSR

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera